Bottom line
IBB vs SHPAX: the short answer
IBB (iShares Biotechnology ETF) and SHPAX (Health & Biotechnology Portfolio) are quite different portfolios: only about 24% of their top holdings (by weight) are shared.
But IBB is far broader, holding 254 positions to 29 for SHPAX, so beyond the top names it adds exposure SHPAX doesn't have.
IBB is cheaper at 0.44% vs 3% — a difference of $256 a year per $10,000 invested.
Over five years, SHPAX returned +3.1% a year vs +2.5% for IBB (reporting dates differ).
SHPAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
IBB vs SHPAX side by side
| IBB | SHPAX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | iShares | Saratoga Advantage |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.44% | 3% |
| Annual cost per $10k | $44 | $300 |
| 10-yr cost on $10k (prospectus) | $555 | $3,702 |
| Max front load | None | 5.75% |
| 12b-1 fee | 0% | — |
| 1-yr return | +28.0% | −5.5% |
| 5-yr return (annualized) | +2.5% | +3.1% |
| 10-yr return (annualized) | +4.4% | +4.1% |
| Best quarter | +26.8% | +15.0% |
| Worst quarter | −22.9% | −13.0% |
| Net assets (fund) | $5.9B | $10.5M |
| Number of holdings | 254 | 29 |
| Portfolio turnover | 27% | 22% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | IBB | SHPAX | Difference |
|---|---|---|---|
| 2024 | −2.4% | +0.3% | −2.7% |
| 2023 | +3.6% | −0.4% | +4.0% |
| 2022 | −13.6% | +2.0% | −15.6% |
| 2021 | +1.0% | +16.7% | −15.7% |
| 2020 | +25.9% | +3.6% | +22.3% |
| 2019 | +24.8% | +16.2% | +8.6% |
| 2018 | −9.1% | −5.5% | −3.7% |
| 2017 | +21.2% | +12.0% | +9.3% |
| 2016 | −21.5% | −2.0% | −19.6% |
| 2015 | +11.5% | +6.9% | +4.6% |
Source: Fund prospectus bar charts
Holdings overlap
8 of IBB's top 25 holdings also appear in SHPAX's top 25.
| Holding | IBB | SHPAX |
|---|---|---|
| Vertex Pharmaceuticals, Inc. | 7.66% | 3.36% |
| Gilead Sciences, Inc. | 7.52% | 3.94% |
| Amgen, Inc. | 7.50% | 5.04% |
| Regeneron Pharmaceuticals, Inc. | 5.70% | 3.93% |
| United Therapeutics Corp. | 1.82% | 6.17% |
| Incyte Corp. | 1.62% | 2.89% |
| Medpace Holdings, Inc. | 1.16% | 3.37% |
| Exelixis, Inc. | 1.07% | 4.55% |
Source: SEC Form N-PORT
IBB top 10
- BlackRock Funds III — 13.18%
- Vertex Pharmaceuticals, Inc. — 7.66%
- Gilead Sciences, Inc. — 7.52%
- Amgen, Inc. — 7.50%
- Regeneron Pharmaceuticals, Inc. — 5.70%
- Alnylam Pharmaceuticals, Inc. — 5.68%
- IQVIA Holdings, Inc. — 3.18%
- Argenx SE — 3.15%
- Insmed, Inc. — 2.95%
- Mettler-Toledo International, Inc. — 2.49%
SHPAX top 10
- Cardinal Health Inc — 6.44%
- Jazz Pharmaceuticals Plc — 6.19%
- United Therapeutics Corp — 6.17%
- Amgen Inc — 5.04%
- Mckesson Corp — 4.90%
- Lantheus Holdings Inc — 4.64%
- Exelixis Inc — 4.55%
- Novartis Ag — 4.50%
- Cencora Inc — 4.33%
- Gilead Sciences Inc — 3.94%
FAQ
What is the difference between IBB and SHPAX?
Which is cheaper, IBB or SHPAX?
Should I own both IBB and SHPAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.